MedTrace Logo

A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)

NCT02147938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 578

Last updated 2024-11-01

No results posted yet for this study

Summary

Assessment in a real situation of the conversion conditions, the efficacy and the safety of the treatment with tacrolimus in renal transplant patients converted from the tacrolimus twice per day form (Prograf®) to the tacrolimus once per day form (Advagraf®) with follow-up at one year.

Analysis of two groups of patients: patients converted from Prograf® to Advagraf® early (during the first 6 months post-transplantation) or late (between 6 and 12 months post-transplantation).

Conditions

  • Renal Transplantation

Interventions

DRUG

Tacrolimus

oral

Sponsors & Collaborators

  • Astellas Pharma S.A.S.

    lead INDUSTRY

Principal Investigators

  • Medical and Scientific Affairs Manager, Transplantation · Astellas Pharma S.A.S.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-17
Primary Completion
2017-05-15
Completion
2017-05-15

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02147938 on ClinicalTrials.gov